Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical trial, a pretzel-shaped device that slowly releases chemotherapy drugs ...

Scientists have found that preserving lymph nodes during cancer surgery could dramatically improve how patients respond to immunotherapy. The research shows that lymph nodes are essential for training ...